Artelo biosciences to present at the q4 investor summit on november 17th

Solana beach, california--(newsfile corp. - november 11, 2021) - artelo biosciences, inc. (nasdaq: artl), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that management will present at the q4 investor summit, hosted by the investor summit group, being held virtually on november 16-17, 2021.gregory gorgas, president and chief executive officer of artelo biosciences, is scheduled to present as follows: ev
ARTL Ratings Summary
ARTL Quant Ranking